Literature DB >> 32281329

[Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway].

Yue Ren1, Mei-Cun Yao2, Xiao-Qian Huo1, Yu Gu1, Wei-Xing Zhu3, Yan-Jiang Qiao1, Yan-Ling Zhang1.   

Abstract

Since the outbreak of 2019-nCoV, the epidemic has developed rapidly and the situation is grim. LANCET figured out that the 2019-nCoV is closely related to "cytokine storm". "Cytokine storm" is an excessive immune response of the body to external stimuli such as viruses and bacteria. As the virus attacking the body, it stimulates the secretion of a large number of inflammatory factors: interleukin(IL), interferon(IFN), C-X-C motif chemokine(CXCL) and so on, which lead to cytokine cascade reaction. With the exudation of inflammatory factors, cytokines increase abnormally in tissues and organs, interfering with the immune system, causing excessive immune response of the body, resulting in diffuse damage of lung cells, pulmonary fibrosis, and multiple organ damage, even death. Arachidonic acid(AA) metabolic pathway is principally used to synthesize inflammatory cytokines, such as monocyte chemotactic protein 1(MCP-1), tumor necrosis factor(TNF), IL, IFN, etc., which is closely related to the occurrence, development and regression of inflammation. Therefore, the inhibition of AA metabolism pathway is benefit for inhibiting the release of inflammatory factors in the body and alleviating the "cytokine storm". Based on the pharmacophore models of the targets on AA metabolic pathway, the traditional Chinese medicine database 2009(TCMD 2009) was screened. The potential herbs were ranked by the number of hit molecules, which were scored by pharmacophore fit value. In the end, we obtained the potential active prescriptions on "cytokine storm" according to the potential herbs in the "National novel coronavirus pneumonia diagnosis and treatment plan(trial version sixth)". The results showed that the hit components with the inhibitory effect on AA were magnolignan Ⅰ, lonicerin and physcion-8-O-β-D-glucopy-ranoside, which mostly extracted from Magnoliae Officinalis Cortex, Zingiberis Rhizoma Recens, Lonicerae Japonicae Flos, Rhei Radix et Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma, Scutellariae Radix, Gardeniae Fructus, Ginseng Radix et Rhizoma, Arctii Fructus, Dryopteridis Crassirhizomatis Rhizoma, Paeoniaeradix Rubra, Dioscoreae Rhizoma. Finally the anti-2019-nCoV prescriptions were analyzed to obtain the potential active prescriptions on AA metabolic pathway, Huoxiang Zhengqi Capsules, Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Qingfei Paidu Decoction, Xuebijing Injection, Reduning Injection and Tanreqing Injection were found that may prevent 2019-nCoV via regulate cytokines. This study intends to provide reference for clinical use of traditional Chinese medicine to resist new coronavirus.

Entities:  

Keywords:  "cytokine storm"; 2019-nCoV; arachidonic acid metabolic pathway; traditional Chinese medicine; virtual screening

Mesh:

Substances:

Year:  2020        PMID: 32281329     DOI: 10.19540/j.cnki.cjcmm.20200224.405

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  19 in total

1.  Treatment efficacy of Lianhua Qingwen capsules for eraly-stage COVID-19.

Authors:  Si-Jia Fan; Jian-Kun Liao; Liu Wei; Bai-Yu Wang; Liu Kai; Du-Xun Tan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

2.  Establishment and validation of a drug-target microarray for SARS-CoV-2.

Authors:  Peng Chen; Zehua Zeng; Hongwu Du
Journal:  Biochem Biophys Res Commun       Date:  2020-07-21       Impact factor: 3.575

Review 3.  Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.

Authors:  Chang Li; Lin Wang; Linzhu Ren
Journal:  Virus Res       Date:  2020-06-24       Impact factor: 3.303

Review 4.  Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).

Authors:  Yu-Feng Huang; Chen Bai; Fan He; Ying Xie; Hua Zhou
Journal:  Pharmacol Res       Date:  2020-05-21       Impact factor: 7.658

Review 5.  Potential Therapeutic Effect of Traditional Chinese Medicine on Coronavirus Disease 2019: A Review.

Authors:  Qin Qiu; Yuge Huang; Xiaohua Liu; Fangfang Huang; Xiaoling Li; Liao Cui; Hui Luo; Lianxiang Luo
Journal:  Front Pharmacol       Date:  2020-11-09       Impact factor: 5.810

Review 6.  Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19.

Authors:  Yu-Jie Dai; Shi-Yao Wan; Shuai-Shuai Gong; Jin-Cheng Liu; Fang Li; Jun-Ping Kou
Journal:  Chin J Nat Med       Date:  2020-12

7.  Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report.

Authors:  Na Zhi; Qian Mo; Shuo Yang; Yuan-Xing Qin; Hao Chen; Zeng-Guang Wu; Cai-Hong Lan; Jun Zhang; Yin-Long Li
Journal:  J Integr Med       Date:  2020-12-05

Review 8.  Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development.

Authors:  Ailin Yang; Yanjun Wu; Ganggang Yu; Haoyan Wang
Journal:  Respir Res       Date:  2021-07-14

Review 9.  Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects.

Authors:  Liu-Cheng Li; Zhi-Hui Zhang; Wen-Cheng Zhou; Jie Chen; Hua-Qian Jin; Hong-Mei Fang; Qin Chen; Ye-Cheng Jin; Jiao Qu; Lian-Di Kan
Journal:  Biomed Pharmacother       Date:  2020-08-19       Impact factor: 6.529

Review 10.  The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis.

Authors:  Xufei Luo; Xiaojia Ni; Jiahui Lin; Yidan Zhang; Lei Wu; Donghui Huang; Yuntao Liu; Jianwen Guo; Wanxin Wen; Yefeng Cai; Yaolong Chen; Lin Lin
Journal:  Phytomedicine       Date:  2020-07-11       Impact factor: 5.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.